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ABSTRACT
Background: Selective serotonin reuptake inhibitors (SSRIs) have increasingly
replaced tricyclic antidepressants (TCAs) in the treatment of depression. They appear
to be safer in overdose, but there is little information on their spectrum of toxicity in
overdose, or relative toxicity of each agent. Objective: To determine the effect of
SSRIs in overdose, as a group, and the relative toxicity of five different SSRIs.
Methods: A review of consecutive SSRI poisoning admissions to a single toxicology
unit. Outcomes examined were length of stay [LOS], intensive care [ICU] admission
rate, coma, seizures, electrocardiographic [ECG] abnormalities, and presence of
serotonin syndrome [SS]. Logistic regression was used to model the outcome QTc
>440 msec. Results: There were 469 SSRI poisoning admissions analyzed after
exclusions. The median LOS for all SSRI overdose admissions was 15.3 h (IQR:
10.5–21.3) and 30 of 469 (6.4%; 95% CI 4.3–9.0%) cases were admitted to ICU. The
incidence of seizures was 1.9% and coma was 2.4%. Serotonin syndrome occurred in
14% of overdoses. Comparison of median QTc intervals of the five SSRIs was
significantly different (p=0.0002); citalopram (450 IQR: 436–484) was individually
different to fluoxetine (p=0.045), fluvoxamine (p=0.022), paroxetine (p=0.0002),
and sertraline (p=0.001). The proportion of citalopram overdoses with a QTc >440
*Correspondence: Dr. Geoffrey K. Isbister, B.Sc., M.B.B.S., F.A.C.E.M., Lecturer; Consultant Clinical Toxicologist and
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msec was 68%, differing significantly from sertraline (adjusted OR: 5.11 95% CI
2.32–11.27). Comparison of median QT intervals of the five SSRIs was statistically
different (p=0.026); citalopram (400 IQR: 380–440) was individually different from
sertraline (p=0.023). Conclusions: This study shows SSRIs are relatively safe in
overdose despite serotonin syndrome being common. The exception was citalopram,
which was significantly associated with QTc prolongation. We believe that cardiac
monitoring should be considered in citalopram overdose, particularly with large
ingestions and patients with associated cardiac disease.
Key Words: SSRI; Serotonin; Overdose; Toxicity; Poisoning; Citalopram;
Paroxetine; Fluoxetine; Sertraline; Serotonin syndrome.
INTRODUCTION
The commercial success of the selective serotonin
reuptake inhibitors (SSRIs) over the past 10 yrs in the
treatment of depression (1,2) is in part due to an
improved adverse effect profile (2) and in part to less
toxicity following overdoses when compared with
tricyclic antidepressants (TCAs) (3,4). The relative
safety in overdose of SSRIs is supported both by case
series (4–10) and studies of deaths per numbers of
prescriptions (11,12). As antidepressants are likely to
be over-represented in overdose (4,13) it is important
to consider their toxicity in that context in individual
prescribing or regulatory decisions. These considera-
tions have been reflected in a reduction in prescription
numbers of TCAs and an increase in prescription num-
bers of SSRIs (1). There has also been a corresponding
reduction in TCA overdoses and an increase in SSRI
overdoses (14).
The most commonly reported effect following
SSRI overdose is serotonin syndrome (SS) (15). Other
reported effects include coma, seizures, and cardiac
toxicity. There is current concern that particular SSRIs
have relatively more cardiotoxicity (QT prolongation
and arrhythmias) and neurotoxicity (seizures and coma)
based on case reports (16–18). Previous experience has
demonstrated that there is considerable variation in
toxicity within drug classes (13,19). However, there
have been no large well-designed comparative studies
of the toxicity of individual SSRIs in overdose.
Five pure SSRIs are available in Australia: fluox-
etine, fluvoxamine, paroxetine, sertraline, and citalo-
pram (3). To determine the effect of SSRIs in overdose
as a group and the relative toxicity of five different
SSRIs we examined a cohort of SSRI overdoses pre-
senting to a single center. We have focused on cardiac
toxicity, neurotoxicity, and serotonin syndrome, as well
as examining the surrogate outcomes length of hospital
stay (LOS) and intensive care (ICU) admission rate.
METHODS
The Hunter Area Toxicology Service (HATS) is a
regional toxicology unit situated at the Newcastle Mater
Misericordiae Hospital that services a population of
about 350,000 people and is a tertiary referral center for
about half-a-million people (20). All presentations and
admissions to the HATS with drug overdose are
prospectively entered into a clinical database (21). A
validated preformatted admission sheet is used by
medical staff to record history and physical signs on
admission (22). This and additional information from the
medical records is entered into the database by two
independent trained personnel at the time of patient
discharge. Data retrieval from the database is done by an
individual blinded to any hypotheses being tested at the
time. There was no review or further information
retrieved from case records after formulation of the
research questions.
Detailed demographic and clinical information is
recorded and from this data set, for all cases of SSRI
poisoning admission, the following information was
obtained: demographics (age, gender), details of over-
dose (amount in defined daily doses [DDD], time to
presentation), clinical effects (temperature, heart rate,
blood pressure, ECG parameters [QT, QTc, QRS],
arrhythmia, seizure, Glasgow Coma Score (GCS) on
admission, serotonin syndrome (SS) [Sternbach criteria
(23) and clinical assessment]), LOS, and ICU admission.
Consecutive single SSRI poisoning admissions
were included from the HATS database between January
1987 and July 2003. Cases of SSRI poisoning were
defined as ingestions of more than the maximum
recommended daily dose: fluoxetine (>60 mg), fluvox-
amine (>200 mg), paroxetine (>60 mg), sertraline
(>200 mg), and citalopram (>60 mg). All admissions
in which a TCA, monoamine oxidase inhibitor, ven-
lafaxine, nefazodone, mianserin, or lithium was coin-
gested were excluded, as well as cases where two SSRIs
278 Isbister et al.
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were coingested. The resulting main data set was used
to create two subsets for analysis of specific toxicities.
. Subset 1 for LOS, ICU admission, neurological
toxicity, and serotonin toxicity.
. Subset 2 for cardiac toxicity.
Only the first admission was included for subset 1
and only one ECG/admission pair for subset 2 (see
below). Second and subsequent admissions were
excluded to remove the bias of an individual’s
susceptibility to a particular drug.
Subset 1
Subset 1 was used to analyze general outcomes,
neurotoxic effects (seizure and coma), and SS. Coinges-
tion of agents known to cause SS or agents with known
serotonin receptor blocking action were determined.
Cases of SS were defined as 1) those fulfilling
Sternbach’s criteria where the attending clinical
toxicologist also diagnosed SS, or 2) the attending
clinical toxicologist diagnosed SS and treated the
patient with a 5-HT2 receptor antagonist (cyprohepta-
dine, chlorpromazine). The use of these inclusion
criteria for SS rather than Sternbach’s criteria alone
(23) was because Sternbach’s criteria are not sensitive
or specific enough for the diagnosis of SS in this unit’s
experience (24).
Subset 2—Car diac Toxicity
Subset 2 was used for analysis of cardiac effects.
The subset included admissions in which only an SSRI
was ingested, or in which all coingested substances had
no known cardiotoxic effects, including effects on the
QRS width, QT interval, or QTc (list available from
authors). Cases were only included if the ECG was
done more than 1h after ingestion. Only one admission/
ECG was included for each patient. Where multiple
admissions with ECGs were available, the ECG with
the longest QT interval was used to select the ad-
mission included, because the QT interval was of
most interest.
An ECG control cohort was constructed using the
HATS database of poisoning presentations with single
ingestions of paracetamol, temazepam, oxazepam, or
diazepam. These drugs were used for comparison
because they have no known electrocardiographic effect.
ECGs are collected at the time of the overdose and
the QRS, R–R, and QT intervals are manually
measured and entered into the HATS database by
two trained persons as described previously (25,26).
The QTc (27) was considered abnormal if greater than
440 msec. In addition to ECG parameters, the
incidence of arrhythmia, bradycardia (HR <60 bpm),
tachycardia (HR >100 bpm), and hypotension (systolic
BP <90 mmHg) were analyzed.
Stat ist ical Analysis
The incidences of neurotoxicity (coma and sei-
zures), SS, and cardiovascular effects for each SSRI
ingested were obtained from the datasets. Pearson’s
Chi-squared and Fisher’s Exact tests were used to
determine whether there were statistically significant
associations between the drug ingestion groups and
gender. Median values for the continuous variables
DDD, time to presentation, age, QTc, QT, and QRS
were compared using Kruskal-Wallis nonparametric
ANOVA test; two-tailed P-values were obtained.
Multiple comparisons between all groups were consid-
ered and two-tailed P-values were obtained (Dwass-
Steel-Chritchlow-Fligner).
Univariate analysis on the binary outcome variable
(QTc >440 msec) was conducted using simple logistic
regression. The following potential predictor variables
were included in the univariate and multivariate
analysis: gender, DDD, time to presentation, patient
age (years), HR, and drug ingested (comparison drug
was sertraline as the market leader in Australia).
Multivariate models on the outcome variable were
determined using multiple-logistic regression—employ-
ing both backward and forward stepwise approaches.
The outputs from the final model were reported as odds
ratios (OR), with corresponding 95% confidence inter-
vals (CI). All statistical analyses were conducted in Stata
(version 7, Stata Corporation, Texas) and StatsDirect
(version 1.9.14, Tidestone Technologies Inc.).
RESULTS
There were 10,440 admissions to HATS from
January 13, 1987 to July 29, 2003, and 8,442 were
deliberate self-poisonings. Two SSRIs were coingested
in nine admissions and were excluded. There were 601
single SSRI poisoning admissions, the first admission
occurring in March 1991. Fifty admissions were
excluded because of coingestion of TCAs, monoamine
oxidase inhibitors, lithium, venlafaxine, nefazodone, or
mianserin, leaving 535 admissions in the main data set.
Relative Toxicity of SSRIs in Overdose 279
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Subset 1
Second and subsequent admissions were excluded
from the 535 admissions, leaving 469 observations in
subset 1. Of these 469, 49 patients took an antisero-
tonergic drug (cyproheptadine, clozapine, risperidone,
olanzapine, quetiapine, chlorpromazine, pericyazine)
and 10 took amphetamines or amphetamine derivatives.
The patients’ ages ranged from 14 to 77 years, with a
median of 30 years (Interquartile Range [IQR]: 21–
39), and 310 (66%) were female. The median LOS for
all SSRI overdose admissions was 15.3 h (IQR: 10.5–
21.3). There was no significant difference between any
of the SSRIs in LOS. Thirty of the 469 (6.4%; 95% CI
4.3–9.0%) cases were admitted to ICU.
The incidences of seizures and GCS <9 on
admission are listed for each SSRI in Table 1. There
were nine seizures in the group of 469 SSRI overdoses
(1.9%; 95% CI 0.8–3.6%). All seizures were short and
self-limiting. Proconvulsant drugs were not excluded in
the analysis, and in two cases the seizure could
possibly be explained by the coingestants. Only 11 of
the 469 (2.4%; 95% CI 1.2–4.2%) patients had a GCS
<9. In 10 of the 11 cases the patient coingested a
significant amount of a sedative agent.
Sixty-seven of the 469 (14.3%; 95% CI: 11.3–
17.8) SSRI admissions developed SS. Forty-three were
treated with a 5-HT2a antagonist (cyproheptadine or
chlorpromazine). Only one patient had a temperature
over 38 degrees Celsius. There were no cases of severe
SS requiring ICU admission or causing hypertonia and
ventilatory failure. Table 1 gives the proportion of
cases with SS by drug type. If all patients coingesting
either antiserotonergic drugs or serotonergic drugs are
excluded, the incidence of SS is not significantly
different at 14.8%. There was a nonsignificant decrease
in the proportion with SS to 10.4% in patients
coingesting antiserotonergic drugs.
Subset 2 Car diac Toxicity
For subset 2, another 142 admissions were
excluded from the 535 admissions due to coingestion
with a cardiotoxic drug, leaving 393 cases; 83 of these
had no ECG or missing data (21%), leaving 310
admissions with 443 ECGs. Thirteen cases were
excluded because ECGs were done less than 1 h after
ingestion. Only including one ECG per patient, there
were 297 admissions of single SSRI ingestions for
analysis of cardiac effects, including citalopram (57),
sertraline (103), paroxetine (78), fluoxetine (42), and
fluvoxamine (17). The comparison group contained
318 patients ingesting non-cardiotoxic medications.
Table 2 gives the comparisons made between the
five SSRIs and the comparison group, and the median
QT, QTc, and QRS of each. Comparison of the median
QTc intervals of the five SSRI groups was significantly
different (p=0.0002). Pairwise comparisons of QTc
showed that citalopram (450 IQR: 436–484) was sta-
tistically significantly different to fluoxetine (p=0.045),
fluvoxamine (p=0.022), paroxetine (p=0.0002), and
sertraline (p=0.001). The median QTc for 318 poi-
soned patients not taking cardiotoxic drugs was
423 msec. The median uncorrected QT intervals of
the five SSRI groups were significantly different
(p=0.026). Pairwise comparisons of QT showed that
citalopram (400 IQR: 360–440) was statistically
significantly different from sertraline (p=0.023). There
were no significant differences in QRS width between
SSRIs or the comparison group.
Left bundle branch block occurred in one citalo-
pram overdose and transient atrial fibrillation in one
fluoxetine overdose (Table 3). Bradycardia occurred in
25 of the 297 SSRI overdoses (8.4%), and tachycardia
occurred in 45 SSRI overdoses (15.2%) and there were
no significant differences between individual SSRIs
(Table 3). Sixty-eight percent of citalopram overdoses
had a QTc >440 msec, and 12% had a QTc >500 msec
which was greater than other SSRIs (Table 3).
LOGISTIC REGRESSION
The multivariate model for the outcome of QTc
> 440, produced by logistic regression, is shown in
Table 1. Incidence of neurotoxicity (coma and seizures) and serotonin syndrome for each type of SSRI ingested.
Sertraline Paroxetine Fluvoxamine Fluoxetine Citalopram
No. of cases (N) 156 119 23 75 96
Seizures 3 (2%) 2 (2%) 1 (4%) 1 (1%) 2 (2%)
Coma 4 (3%) 2 (2%) 0 1 (1%) 4 (4%)
Serotonin syndrome 31 (20%) 22 (18%) 4 (17%) 1 (1%) 9 (9%)
280 Isbister et al.
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Table 4. Of the potential predictor variables considered,
HR, gender, drug ingestion groups and DDD were
statistically significant. Hence, adjusting for HR (incre-
ments of 10 bpm) [OR: 1.67; 95% CI: 1.40–1.97],
gender [2.51; 95% CI: 1.39–4.53] and DDD (incre-
ments of 10 units) [OR: 1.22; 95% CI: 1.02–1.47], the
patients ingesting citalopram [OR: 5.11; 95% CI: 2.32–
11.27] were more likely to have a QTc >440 compared
to those who had ingested sertraline (reference group).
DISCUSSION
This series of SSRI overdoses admitted to a single
toxicology unit investigates the relative toxicity of
individual SSRIs and establishes effects that are
common to the SSRIs drug class following overdose.
Case reports of SSRI poisoning have indicated that
severe toxicity can occur (2,3). This study helps define
the frequency of these more severe effects and the
spectrum of toxicity of SSRIs overdose.
The study confirms that the majority of SSRIs are
safe in overdose. There were no deaths in the study.
Although deaths have been reported following massive
single ingestion overdoses of all SSRIs (2,3,8,17), this
is exceedingly uncommon compared to TCAs (11). The
LOS was slightly less than for all overdoses seen by
the same unit, and the admission rate to ICU of 6.4%
was much less than all overdoses seen in the same unit
of 16% (29). Coma was rare (nine cases) and did not
occur in the SSRI-alone group, thus the presence of
coma makes a pure SSRI overdose unlikely. There was
a low incidence of seizures and significantly less than
both TCAs and venlafaxine (30).
Citalopram compared to the other four SSRIs was
potentially more cardiotoxic in overdose, with signif-
icant effects on the QT interval. The median QTc
interval of citalopram overdoses was greater than
440 msec, and the proportion of cases with a QTc
greater than 440 msec was 5.1 times that of sertraline
(the most commonly prescribed SSRI in Australia).
The median QT interval for citalopram overdoses was
also significantly different from other SSRIs, partially
excluding the possibility that a difference in heart rate
was a confounder in the QTc finding. Premarketing and
postmarketing studies of citalopram demonstrated that
in therapeutic doses citalopram does not a effect the
QTc interval (31). However, previous retrospective
studies of citalopram overdoses did demonstrate an
increased QTc interval in a third of patients taking
greater than 600 mg (9,10). There have been two
reported cases of Torsades de Pointes occurring
following citalopram overdose (32,33). Left bundle
branch block has been previously reported in citalo-
pram overdose (34) and again occurred in this study.
There were a number of limitations of the study
including the use of a single ECG to investigate the
ECG effects in overdose. A control group was developed
for comparison, which controlled to some extent for
other factors, physical or psychological, that might
Table 4. Logistic regression: Outcome of interest is QTc
>440 msec.
Predictors Odds ratio 95% CI
Drug ingested
Sertraline (reference) –
Paroxetine 1.38 0.69–2.77
Fluvoxamine 0.70 0.19–2.51
Fluoxetine 1.00 0.43–2.34
Citalopram 5.11 2.32–11.27
Heart rate
(10 unit increases)
1.67 1.40–1.97
DDD (10 unit increases) 1.22 1.02–1.47
Males (reference) –
Females 2.51 1.39–4.53
Adjusted odds ratios with 95% confidence interval (95% CI).
Table 3. Cardiovascular effects (arrhythmias, bradycardia, tachycardia, and hypotension).
Sertraline Paroxetine Fluvoxamine Fluoxetine Citalopram
No. of cases (N) 103 78 17 42 57
Arrhythmia/conduction block* 0 0 0 1 (2.4%) 1 (1.8%)
Bradycardia 8 (8%) 6 (8%) 1 (6%) 3 (7%) 7 (12%)
Tachycardia 20 (19%) 8 (10%) 0 7 (17%) 10 (18%)
Hypotension 0 0 0 0 2 (3.5%)
QTc >440 msec 41 (40%) 31 (40%) 4 (24%) 15 (36%) 39 (68%)
QTc >500 msec 6 (6%) 1 (1%) 1 (6%) 4 (10%) 7 (12%)
*Excluding bradycardia and tachycardia.
282 Isbister et al.
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confound the results in poisoned patients. The logistic
regression also corrected for some of these factors and
demonstrated the expected finding that QTc prolonga-
tion is significantly more common in females (35), with
increasing HR and with increasing dose. This finding
further confirms the validity of the sample used.
There has been considerable discussion about the
assessment of drugs at risk of causing sudden cardiac
death in therapeutic doses and overdose, and the
importance of the QT/QTc interval for predicting
arrhythmias (35,36). The U.S. Food and Drug Admin-
istration suggests comparison of mean QTc as well as
the proportion of abnormal QTc intervals, as indicators
for therapeutic doses (36). We used both of these
methods to assess the QT interval. We demonstrated a
significant effect on the QTc in citalopram overdoses.
However, a prolonged QTc is only a marker, not a
predictor, of sudden cardiac death or arrhythmias such
as Torsades de Pointes (36). Nevertheless, citalopram
should be regarded as potentially cardiotoxic in
overdose without larger studies of SSRI overdoses.
With the introduction of the SSRIs and other newer
antidepressants SS has become a common presentation
in the overdose patient (15,23). In this study we
considered all SSRI overdoses to determine the severity
and incidence of SS in SSRI overdoses. This revealed
that SS was common, occurring in 14% of cases. None
of the patients developed severe or life-threatening SS.
Previous reports have suggested some of the SSRIs do
not cause SS (9). This study showed that it is equally
likely with paroxetine, sertraline, and fluvoxamine, but
less common with citalopram and fluoxetine (Table 1).
The very low incidence of SS in fluoxetine overdoses
may be due to the majority of cases occurring early in
the 1990s prior to a clearer definition of SS being
developed by HATS. The lower incidence with citalo-
pram (most recently introduced drug in Australia) is
more difficult to explain and has been suggested in a
previous study of citalopram overdoses (9). It is possible
that this is due to citalopram being a racemic mixture of
an S(+)- and R( )-enantiomer and one of these being
less active. A study in rats has shown that the 5-HT
reuptake inhibitory activity of citalopram resides in the
S(+)-enantiomer, while the R( )-enantiomer counteracts
this effect (37).
Indicators of severity or outcomes of overdose are
often difficult to measure in studies of poisoned
patients. Important outcomes of toxicity that indicate
severity, such as seizures, arrhythmias, coma, and
death are usually rare. It is often difficult to do studies
with large enough numbers of single-agent overdose to
measure these. In this study we were not able to
evaluate these outcomes, except coma, which was
shown to be less common in SSRI poisoning. Often
surrogate measures such as LOS and ICU admission
rate are used because they can be effectively measured
and compared in smaller studies. HATS has been
staffed by the same clinicians throughout its existence,
and management protocols (including admission crite-
ria to ICU and discharge policies) have been con-
sistently applied throughout. Thus, although LOS and
ICU admission rates may be influenced by factors
other than the toxicity of the drug, they can be used for
comparison between drugs and are additionally a useful
measure of institutional resource use in poisoning.
Drug concentrations were not available for patients
in this study because they are not part of the routine
collection of prospective data for HATS. However, all
poisoned patients admitted to HATS have the drug of
ingestion confirmed by history-taking on at least two
occasions, and this is confirmed with collateral history
from family and friends, as well as evidence of empty
drug containers. Previous studies of overdose have
demonstrated that this corresponds to definite ingestion
in the majority of cases (38,39) and has been
confirmed with quetiapine overdose presenting to
HATS (26).
This study shows that the SSRIs as a group are
relatively safe in overdose despite the occurrence of
SS. The important exception was citalopram, which
was significantly associated with QTc prolongation.
This provides a biologically plausible basis for the
reports of increased morbidity and mortality associated
with citalopram overdose (9,16,17,32,33) and at least
two cases of Torsades de Pointes that have been
reported (32,33). It also identifies citalopram as the
only SSRI where routine cardiac monitoring may be
justified for large overdoses, particularly in patients
with a QTc >500 msec.
CONFLICTS OF
INTEREST STATEMENT
There were no conflicts of interest for the authors.
ACKNOWLEDGMENTS
We would like to thank Debbie Whyte and Toni
Nash for data entry and manual measurements of the
ECG parameters. We would also thank Stuart Allen for
data extraction.
Relative Toxicity of SSRIs in Overdose 283
D
ow
nl
oa
de
d 
by
 [D
ea
ki
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
] a
t 2
1:
53
 1
7 
Ja
nu
ar
y 
20
16
 
REFERENCES
1. McManus P, Mant A, Mitchell PB, Montgomery
WS, Marley J, Auland ME. Recent trends in the
use of antidepressant drugs in Australia, 1990–
1998. Med J Aust 2000; 173:458–461.
2. Mourilhe P, Stokes PE. Risks and benefits of
selective serotonin reuptake inhibitors in the
treatment of depression. Drug Safety 1998;
18:57–82.
3. Barbey JT, Roose SP. SSRI safety in overdose. J
Clin Psychiatry 1998; 59(suppl. 15):42–48.
4. Stoner SC, Marken PA, Watson WA, Switzer JL,
Barber MF, Meyer VL, Sommi RW Jr, Steele MT.
Antidepressant overdoses and resultant emergency
department services: the impact of SSRIs. Psycho-
pharmacol Bull 1997; 33:667–670.
5. Borys DJ, Setzer SC, Ling LJ, Reisdorf JJ, Day
LC, Krenzelok EP. Acute fluoxetine overdose: a
report of 234 cases. Am J Emerg Med 1992;
10:115–120.
6. Klein-Schwartz W, Anderson B. Analysis of
sertraline-only overdoses. Am J Emerg Med
1996; 14:456–458.
7. Myers LB, Krenzelok EP. Paroxetine (Paxil)
overdose: a pediatric focus. Vet Hum Toxicol
1997; 39:86–88.
8. Garnier R, Azoyan P, Chataigner D, Taboulet P,
Dellattre D, Efthymiou ML. Acute fluvoxamine
poisoning. J Int Med Res 1993; 21:197–208.
9. Personne M, Sjo¨berg G, Persson H. Citalopram
overdose—review of cases treated in Swedish
hospitals. J Toxicol, Clin Toxicol 1997; 35:237–
240.
10. Personne M, Persson H, Sjo¨berg G. Citalopram
toxicity. Lancet 1997; 350:518–519.
11. Buckley NA, McManus PR. The fatal toxicity
index (FTI) of antidepressant drugs in the UK
between 1993 & 1998. J Toxicol, Clin Toxicol
2001; 39:489–490.
12. Mason J, Freemantle N, Eccles M. Fatal toxicity
associated with antidepressant use in primary care.
Br J Gen Pract 2000; 50:366–370.
13. Buckley NA, Dawson AH, Whyte IM, Henry DA.
Greater toxicity in overdose of dothiepin than of
other tricyclic antidepressants. Lancet 1994;
343:159–162.
14. Townsend E, Hawton K, Harriss L, Bale E, Bond
A. Substances used in deliberate self-poisoning
1985–1997: trends and associations with age,
gender, repetition and suicide intent. Soc Psychi-
atry Psychiatr Epidemiol 2001; 36:228–234.
15. Lane R, Baldwin D. Selective serotonin reuptake
inhibitor-induced serotonin syndrome: review. J
Clin Psychopharmacol 1997; 17:208–221.
16. Grundemar L, Wohlfart B, Lagerstedt C, Bengts-
son F, Eklundh G. Symptoms and signs of severe
citalopram overdose. Lancet 1997; 349:1602.
17. Ostrom M, Eriksson A, Thorson J, Spigset O. Fatal
overdose with citalopram. Lancet 1996; 348:339–
340.
18. Kincaid RL, McMullin MM, Crookham SB,
Rieders F. Report of a fluoxetine fatality. J Anal
Toxicol 1990; 14:327–329.
19. Buckley NA, Whyte IM, Dawson AH. Cardiotox-
icity more common in thioridazine overdose than
with other neuroleptics. J Toxicol, Clin Toxicol
1995; 33:199–204.
20. Buckley NA, Whyte IM, Dawson AH, McManus
PR, Ferguson NW. Self-poisoning in Newcastle,
1987–1992. Med J Aust 1995; 162:190–193.
21. Whyte IM, Buckley NA, Dawson AH. Data
collection in clinical toxicology: are there too
many variables? J Toxicol, Clin Toxicol 2002;
40:223–230.
22. Buckley NA, Whyte IM, Dawson AH, Reith DA.
Preformatted admission charts for poisoning
admissions facilitate clinical assessment and re-
search. Ann Emerg Med 1999; 34:476–482.
23. Sternbach H. The serotonin syndrome. Am J
Psychiatry 1991; 148:705–713.
24. Isbister GK, Dawson A, Whtye IM. Comment:
serotonin syndrome and 5-HT2A antagonism. Ann
Pharmacother 2001; 35:1143–1144.
25. Buckley NA, O’Connell DL, Whyte IM, Dawson
AH. Interrater agreement in the measurement of
QRS interval in tricyclic antidepressant overdose:
implications for monitoring and research. Ann
Emerg Med 1996; 28:515–519.
26. Balit CR, Isbister GK, Whyte IM. Quetiapine poi-
soning: a case series. Ann Emerg Med 2003;
42:751–758.
27. Bazett H. An analysis of the time-relations of
electrocardiograms. Heart 1920; 7:353–370.
28. Moss AJ. Measurement of the QT interval and the
risk associated with QTc interval prolongation: a
review. Am J Cardiol 1993; 72:23B–25B.
29. Isbister GK, Balit CR, Whyte IM, Dawson A.
Valproate overdose: a comparative cohort study of
self poisonings. Br J Clin Pharmacol 2003;
55:398–404.
30. Whyte IM, Dawson AH, Buckley NA. Relative
toxicity of venlafaxine and selective serotonin
reuptake inhibitors in overdose compared to
tricyclic antidepressants. QJM 2003; 96:369–374.
31. Rasmussen SL, Overo KF, Tanghoj P. Cardiac
284 Isbister et al.
D
ow
nl
oa
de
d 
by
 [D
ea
ki
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
] a
t 2
1:
53
 1
7 
Ja
nu
ar
y 
20
16
 
safety of citalopram: prospective trials and retro-
spective analyses. J Clin Psychopharmacol 1999;
19:407–415.
32. Tarabar AF, Hoffman RS, Nelson LS. Citalopram
overdose: late presentation of Torsades de Pointes
(TdP) with cardiac arrest [abstr]. J Toxicol, Clin
Toxicol 2003; 41:676.
33. Meuleman C, Jourdain P, Bellorini M, Sadeg N,
Loiret J, Guillard N, Thebault B, Funck F.
Citalopram and Torsades de Pointes. A case report.
Arch Mal Coeur Vaiss 2001; 94:1021–1024.
34. Snider RD. Case report: left bundle branch block—
a rare complication of citalopram overdose.
J – South Carol Med Assoc 2001; 97:380–382.
35. Malik M, Camm AJ. Evaluation of drug-induced
QT interval prolongation: implications for drug
approval and labelling. Drug Safety 2001; 24:323–
351.
36. Glassman AH, Bigger JT Jr. Antipsychotic drugs:
prolonged QTc interval, torsade de pointes, and
sudden death. Am J Psychiatry 2001; 158:1774–
1782.
37. Mork A, Kreilgaard M, Sanchez C. The R-enan-
tiomer of citalopram counteracts escitalopram-
induced increase in extracellular 5-HT in the
frontal cortex of freely moving rats. Neurophar-
macology 2003; 45:167–173.
38. Dargan PI, Ladhani S, Jones AL. Measuring
plasma paracetamol concentrations in all patients
with drug overdose or altered consciousness: does
it change outcome? Emerg Med J 2001; 18:178–
182.
39. Pohjola-Sintonen S, Kivisto KT, Vuori E. Identi-
fication of drugs ingested in acute poisoning:
correlation of patient history with drug analyses.
Ther Drug Monit 2000; 22:749–752.
Submitted February 25, 2003
Accepted January 20, 2004
Relative Toxicity of SSRIs in Overdose 285
D
ow
nl
oa
de
d 
by
 [D
ea
ki
n 
U
ni
ve
rs
ity
 L
ib
ra
ry
] a
t 2
1:
53
 1
7 
Ja
nu
ar
y 
20
16
 
